Clinical Trials for COVID-19: Can we Better Use the Short Window of Opportunity?

Clinical Pharmacology and Therapeutics

Volumn 108, Issue 4, 2020, Pages 730-733

  Eichler, Hans Georg ^a,b   Cavaleri, Marco ^a   Enzmann, Harald ^a,c   Scotti, Francesca ^a   Sepodes, Bruno ^a,d   Sweeney, Fergus ^a   Vamvakas, Spiros ^a   Rasi, Guido ^a,e  

^a EUROPEAN MEDICINES AGENCY   (United Kingdom)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c BfArM   (Germany)

^d UNIVERSITY OF LISBON   (Portugal)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LOPINAVIR PLUS RITONAVIR; REMDESIVIR; SARS-COV-2 VACCINE;

CLINICAL OUTCOME; CLINICAL TRIAL (TOPIC); CLINICAL TRIAL PROTOCOL; CORONAVIRUS DISEASE 2019; EPIDEMIC; EUROPEAN UNION; FUNDING; HUMAN; MEDICAL DECISION MAKING; MULTICENTER STUDY (TOPIC); PANDEMIC; PRIORITY JOURNAL; PROFESSIONAL STANDARD; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESEARCH ETHICS; REVIEW; SCIENTIST; STAKEHOLDER ENGAGEMENT; WORLD HEALTH ORGANIZATION; BETACORONAVIRUS; CORONAVIRUS INFECTION; DRUG CONTROL; DRUG INDUSTRY; MEDICAL RESEARCH; PROCEDURES; TIME FACTOR; UNIVERSITY HOSPITAL; VIRUS PNEUMONIA;

ACADEMIC MEDICAL CENTERS; BETACORONAVIRUS; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; CORONAVIRUS INFECTIONS; DRUG AND NARCOTIC CONTROL; DRUG INDUSTRY; HUMANS; PANDEMICS; PNEUMONIA, VIRAL; TIME FACTORS;

EID: 85085697181     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.1891     Document Type: Review

References (19)

1. World Health Organization (WHO) 'https://www.who.int/teams/blueprint/covid-19'. Accessed April 28, 2020.
2. European Medicines Agency (EMA). Website: Committee for Medicinal Products for Human Use (CHMP). A call to pool EU research resources into large-scale, multi-centre, multi-arm clinical trials against COVID-19 'https://www.ema.europa.eu/en/documents/other/call-pool-eu-research-resources-large-scale-multi-centre-multi-arm-clinical-trials-against-covid-19_en.pdf'. Accessed April 28, 2020.
3. Mullard, A. Flooded by the torrent: the COVID-19 drug pipeline. Lancet 395, 1245–1246 (2020).
4. Gaborit, B.J. et al. Plea for multitargeted interventions for severe COVID-19. Lancet Infect. Dis. doi: https://doi.org/10.1016/S1473-3099(20)30312-1. [epub ahead of print].
5. European Union Clinical Trials Register 'https://www.clinicaltrialsregister.eu\'.
6. World Health Organization (WHO). Website: International clinical trials registry platform (ICTRP) 'https://www.who.int/ictrp/data'.
7. Grein, J. et al. Compassionate use of remdesivir for patients with severe COVID-19. N. Engl. J. Med. doi: https://doi.org/10.1056/NEJMoa2007016. [epub ahead of print].
8. Cao, B. et al. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N. Engl. J. Med. 382, 1787–1799 (2020).
9. Fogel, D.B. Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review. Contemp. Clin. Trials Commun. 11, 156–164 (2018).
10. World Health Organization (WHO). Website: “Solidarity” clinical trial for COVID-19 treatments . Accessed April 28, 2020.
11. European Commission (EC). Website: First ERAvsCorona action plan . Accessed April 28, 2020.
12. White, N. On behalf of COVID-19 Clinical Research Coalition. Lancet 395, 1322–1325 (2020).
13. World Medical Association (WMA). Website: WMA declaration of Helsinki – ethical principles for medical research involving human subjects. . Accessed April 28, 2020.
14. European Clinical Research Infrastructure Network (ECRIN) 'https://www.ecrin.org/'.
15. European Commission (EC). Website: EudraLex Vol 10 - Guidance documents applying to clinical trials questions & answers - paragraphs 50 and 51 'https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-10/ctqa_v11.pdf'. Accessed April 28, 2020.
16. European Medicines Agency (EMA). Website: Guidance to sponsors on how to manage clinical trials during the COVID-19 pandemic 'https://www.ema.europa.eu/en/news/guidance-sponsors-how-manage-clinical-trials-during-covid-19-pandemic'. Accessed April 28, 2020.
17. European Medicines Agency (EMA). Website: Points to consider on implications of Coronavirus disease 4 (COVID-19) on methodological aspects of ongoing clinical 5 trials 'https://www.ema.europa.eu/en/implications-coronavirus-disease-covid-19-methodological-aspects-ongoing-clinical-trials'. Accessed May 13, 2020.
18. European Medicines Agency (EMA). Website: International regulators pledge collective support to combat COVID-19 pandemic 'https://www.ema.europa.eu/en/news/international-regulators-pledge-collective-support-combat-covid-19-pandemic'. Accessed May 13, 2020.
19. Heads of Medicines Agencies (HMA). Website: Clinical Trials Facilitation and Coordination Group (CTFG) 'https://www.hma.eu/ctfg.html'. Accessed May 13, 2020.